Potentials of antiviral therapy at patients with liver cirrhosis in an outcome of HCV-infection
Abstract
Aim of investigation. To study efficacy and complications of antiviral therapy in patients with liver cirrhosis of HCV-etiology.
Material and methods. Original study included 57 patients with liver cirrhosis of HCV-etiology of A and B classes by Child-Pugh, treated in Sverdlovsk regional center of hepatology, based on «Sverdlovsk regional hospital №1» (Yekaterinburg) in 2008 to 2010. All patients were separated into two groups: the first (27 cases) received antiviral therapy (AVT), the second (30 cases) – received no AVT.
Results. The most significant factor of the positive response to AVT (even transient) was presence of non-1-st genotype of the virus C. Differences in average MELD indices in studied groups of patients at the moment of the investigation onset and after its termination show, that AVT allowed to maintain the degree of severity of cirrhosis at initial level without further progression, and in some cases at achievement of the positive response to antiviral treatment, to reach certain regression of disease.
Conclusions. Optimal candidates for antiviral therapy are patients of younger age with the HCV-associated liver cirrhosis of Child-Pugh A and B classes, with non 1-st genotype. At prescription of this treatment it is necessary to take into account high risk of infections development.
About the Author
E. N. Bessonova
Государственное учреждение здравоохранения «Свердловская областная клиническая больница № 1»
Russian Federation
Russian Federation
References
1. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin // J. Hepatol. – 2008. – N 49. – P. 274–287.
2. Berenguer M., Ferrell L., Watson J. et al. HCV-related fibrosis progression following liver transplantation: increase in recent years // J. Hepatol. – 2000. – Vol. 32, N 4. – P. 673–684.
3. Bzowej N., Nelson D., Thommes J. et al. Randomized controlled trial of prophylactically administered peginterferon alfa-2a plus ribavirin vs no prophylaxis following orthotopic liver transplantation for hepatitis C: a report of initial safety and tolerability [abstract] // Hepatology. – 2006. – Vol.44 (suppl 1). – P. 188
4. Сharlton M., Ruppert K., Belle S.H. et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database // Liver Transplant. – 2004. – Vol. 10, N 9. – P. 1120–1130.
5. Crippin J.S., McCashland T., Terrault N. et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation // Liver Transplant. – 2002. – Vol. 8, N 4.– P. 350–355.
6. Everson G.Т. Treatment of patients with hepatitis C virus on the waiting list // J. Hepatol. – 2005. – Vol. 42, N 4. – P. 456–462.
7. Everson G.T., Trotter J., Forman L. et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy // Неpatology. – 2005. – Vol. 42. – P. 255–262.
8. Forman L.M., Lewis J.D., Berlin J.A. et al. The association between hepatitis C infection and survival after orthotopic liver transplantation // Gastroenterology. – 2002. – Vol. 122, N 4. – P. 889–896.
9. Forns X., Navasa M., Rodes J. Treatment of HCV infection in patients with advanced cirrhosis // Hepatology. – 2004. – Vol. 40, N 2. – P. 498–501.
10. Gane E.J., Naoumov N.V., Qian K.P. et al. Longitudinal analysis of hepatitis C virus replication following liver transplantation // Gastroenterology. – 1996. – Vol. 110, N 1. – P. 167–177.
11. Gane E.J., Portmann B.C., Naoumov N.V. et al. Longterm outcome of hepatitis C virus infection after liver transplantation // N. Engl. J. Med. – 1996. – Vol. 334, N 13. – P. 815–820.
12. Guerrero R.B., Batts K.P., Burgart L.J. et al. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study // Modern Pathology. – 2000. – Vol. 13, N 3. – P. 229–237.
13. Iacobellis A., Siciliano M., Perri F. et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis:a controlled study // J. Hepatol. – 2007. – N 46. – P. 206–212.
14. Norah A., Terrault Н. Hepatitis C Therapy Before and After Liver Transplantation. Division of Gastroenterology, Department of Medicine, University of California–San Francisco, San Francisco, CA // Liver Transplant. – 2008. – N 14. – P. 58–66.
15. Sangionvanni A., Prati G.M., Fasani P. et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients // Hepatology. – 2006. – Vol. 43. – P. 1303–1310.
16. Sreekumar R., Gonzalez-Koch A., Maor-Kendler Y. et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation // Hepatology. – 2000. – Vol. 32, N 5. – P. 1125–1130.
17. Tekin F., Gunsar F., Karasu Z. et al. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics // Aliment. Pharmacol. Ther. – 2008. – N 27. – P. 1081–1085.
Review
For citations:
Bessonova E.N. Potentials of antiviral therapy at patients with liver cirrhosis in an outcome of HCV-infection. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011;21(4):43-51. (In Russ.)
Views:
86
Email this article 
